KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Deferred Taxes: 2016-2019

Historic Deferred Taxes for Amneal Pharmaceuticals (AMRX) over the last 4 years, with Dec 2019 value amounting to $371.7 million.

  • Amneal Pharmaceuticals' Deferred Taxes rose 110.06% to $33,000 in Q4 2019 from the same period last year, while for Dec 2019 it was $371.7 million, marking a year-over-year increase of 4038.09%. This contributed to the annual value of $371.7 million for FY2019, which is 4038.09% up from last year.
  • As of FY2019, Amneal Pharmaceuticals' Deferred Taxes stood at $371.7 million, which was up 4,038.09% from -$9.4 million recorded in FY2018.
  • Amneal Pharmaceuticals' 5-year Deferred Taxes high stood at $371.7 million for FY2019, and its period low was -$9.4 million during FY2018.
  • Moreover, its 3-year median value for Deferred Taxes was $742,000 (2017), whereas its average is $121.0 million.
  • Its Deferred Taxes has fluctuated over the past 5 years, first slumped by 1,372.10% in 2018, then surged by 4,038.09% in 2019.
  • Over the past 4 years, Amneal Pharmaceuticals' Deferred Taxes (Yearly) stood at $121,000 in 2016, then spiked by 513.22% to $742,000 in 2017, then plummeted by 1,372.10% to -$9.4 million in 2018, then surged by 4,038.09% to $371.7 million in 2019.